API | fexinidazole

fexinidazole Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Fexinidazole is a medication used to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Some evidence also supports its use in Chagas disease. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1
InChIKey: MIWWSGDADVMLTG-UHFFFAOYSA-N
Mol. Mass: 279.32
ALogP: 2.63 Partition coefficient
ChEMBL Molecule:
fexinidazole

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

fexinidazole | hoe 239

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Chagas Disease (Phase 2)

Healthy Volunteers (Phase 1)

Leishmaniasis, Visceral (Phase 2)

Sleep Disorders, Intrinsic (Phase 3)

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue